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pegvisomant (13%) and bromocriptine (7%). Baseline co-morbidities (CM) included
hypertension (66%), carpal tunnel syndrome (23%), osteoporosis (16%), dyslipide-
mia (12%), visual disturbance (12%), sleep apnea (2%), myocardial infarction (2%)
and renal calculi (2%). Distribution of co-morbidities was statistically significantly
higher than general population (p-value 0.05); specifically those with 1 CM (41%)
or 3 CM (19%) or more. Longitudinal assessment of co-morbidities reported no
statistically significant difference prior and post therapy. CONCLUSIONS: This ret-
rospective analysis of patients diagnosed with acromegaly indicates that they re-
quire substantially higher resource use and experience a high burden of comor-
bidities.
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ADHERENCE: A REAL WORLD RETROSPECTIVE DATABASE STUDY AMONG TYPE
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OBJECTIVES: An important factor to take into account when evaluating the effec-
tiveness of a drug is adherence. Adherence describes the degree to which a patient
correctly follows medical advice. The objective of this study was to evaluate the
factors that determine adherence of adult patients with type 2 diabetes treated
with once-daily injectable liraglutide 1.8mg or twice-daily injectable exenatide
10g.METHODS:A retrospective study was conducted employing US data from the
IMS PharMetrics claims database. The index period ranged from January 2010 to
December 2010 and patients needed to be continuously enrolled 12 months before
and after the index date. Patients were treatment naïve to liraglutide and exenatide
but may not have been injection-naïve as prior insulin use was not part of the
patient selection exclusion criteria, which may have impacted the outcomes as a
limitation of the study. Adherence was measured by continuous Medication Pos-
session Ratio (MPR) as well as a categorical response using MPR (MPR80%high
adherence and MPR80%low adherence). The determinants of adherence were
estimated using multivariable models and bivariate testing was conducted for se-
lection of the possible predictors. Covariates were then included and a stepwise
model-building approach was used. RESULTS: Data from 3623 patients (2036 lira-
glutide 1.8mg and 1587 exenatide 10g) were used in the analyses. When adjusting
for confounding effects, patients treated with exenatide 10g were approximately
11% (p.0001) less adherent than patients treated with liraglutide 1.8mg assessed
by the continuous MPR measure. The odds ratio (OR) for achieving a high categor-
ical MPR for liraglutide 1.8mg compared to exenatide 10g was 1.33 in favor of
liraglutide 1.8mg (p.0001). Variables found to impact the level of adherence were
age, gender, the geographic region, treatment, and percentage co-payment from
the claimant. CONCLUSIONS: The analysis showed that once-daily liraglutide
1.8mg is associated with better adherence than twice-daily exenatide 10g.
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GREECE (LESS STUDY)
Rombopoulos G1, Hatzikou M1, Kossiva E1, Athanasiadis A2, Elisaf M3
1Novartis Hellas, Metamorfosis, Greece, 2Foundation for Economic and Industrial Research
(IOBE), Athens, Greece, 3University Hospital of Ioannina, Ioannina, Greece
OBJECTIVES: To assess the differences in the compliance of Greek patients suffer-
ing from Type 2 diabetes mellitus who receive free combination therapy of met-
formin and vildagliptin compared to the diabetic patients who receive fixed com-
bination therapy of metformin/vildagliptin. METHODS: Eight hundred adult
patients inadequately controlled on twice daily 850mg metformin monotherapy
who were recently added vildagliptin treatment as add on to metformin (fixed dose
combination or free combination) were enrolled in the study. The observation
period was 6 months. Upon treatment initiation each patient received a diary, in
which they had to record their treatment on a daily basis. The diary then was
returned to the physician at the final visit. Additionally, at baseline and at the last
visit of the study, patients were asked to complete a questionnaire related to their
compliance of their indicated treatment. Patients were defined as compliant when
they hadn’t missed any drug dose, received the correct dosage of the medication
and did not interrupt their treatment.RESULTS:The preliminary results the overall
study sample 63% were considered to be compliant. In the between groups analy-
sis, it was found that 56% of patients receiving free combination were compliant
with their treatment compared to a substantially higher 68% of compliant patients
in the fixed combination group (p0,005). Odds Ratio was equal to 1,647, suggesting
that patients receiving free combination were 1.647 times more likely not to com-
ply with their treatment than the patients on fixed combination. A statistically
significant reduction in Hb1Ac was observed in both groups between the first and
last visit (p0,001) but not any difference between two groups, which is attributed
to the short follow-up period. CONCLUSIONS: Patients on fixed dose combination
treatment for Type II Diabetes are more compliant than patients on free dose
combinations. Improved compliance has been shown to improve disease manage-
ment, which can prevent expensive complications.
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OBJECTIVES: Cost-utility analysis of type 2 diabetes mellitus (T2DM) interventions
requires the estimation of utility values. To increase the robustness of such esti-
mates in line with the National Institute for Health and Clinical Excellence (NICE)
requirements a systematic literature review of utility values associated with
T2DM-related complications was performed. METHODS: The review was per-
formed according to NICE methodology recommendations using Medline, Embase,
EconLIT and the NHS Economic Evaluation Database in May 2012. Health utilities
selected were based on the NICE reference case, including a preference for EQ-5D
data and UK population. Landmark study articles reporting multiple utility values
were favoured. RESULTS: A total of 16,578 records were identified. 61 full text
articles were included in the qualitative synthesis. T2DM without complication
values ranged from 0.690 to 0.970. The proposed utility set primarily consisted of
utility values extracted from Clarke 2002 (T2DM without complication: 0.785, myo-
cardial infarction:-0.055, angina:-0.090, heart failure: -0.108, stroke: -0.164, severe
vision loss: -0.074, amputation: -0.28) and Bagust 2005 (peripheral vascular disease:
-0.061, protenuria: -0.048, neuropathy: -0.084, foot ulcer: -0.170 and overweight:
-0.0061 per BMI unit above 25 kg/m2). These values were supplemented by Was-
serfallen 2004 (haemodialysis: 0.621, peritoneal dialysis: 0.581); Kiberd and Jidal
1995 (renal transplant: 0.762); Fenwick (mild non-proliferative diabetic retinopathy
or macular oedema: 0.760, vision threatening diabetic retinopathy: 0.730) as well as
Currie 2006 (major hypoglycaemia: -0.270, minor hypoglycaemia: -0.070). Limita-
tions included the partial lack of studies in a diabetic- or UK-specific population,
the variability in reporting media, mean or values adjusted for confounding factors.
CONCLUSIONS: This set of values should improve the robustness of T2DM modelling
outcomes in line with NICE requirements. Future research could focus on eliciting a
coherent set of values for T2DM-related complications in line with the NICE reference
case and to define the variance around the utility value point estimates.
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THE ADAPTATION OF THE INJECTION PEN ASSESSMENT QUESTIONNAIRE FOR
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OBJECTIVES: To examine the reliability and validity of the Injection Pen Assess-
ment Questionnaire (IPAQ) in a European population. METHODS: The IPAQ is a
29-item measure of objective and comparative ease of use and preference for re-
combinant human growth hormone (rhGH) injection devices based on content
elicited from focus groups and one-on-one interviews of device users. The IPAQ
was included in a Phase 3, open-label, multicenter trial in 136 experienced rhGH
subjects (parent-child dyads) in the United States to test the ease of use and pref-
erence for a new Genotropin® disposable pen (NCT00965484). IPAQ content was
adapted for use in adults and translated into seven languages. Data from a Phase 3,
open-label, multicenter, crossover study (NCT01112865; N120) was used to eval-
uate the psychometric properties of the IPAQ in a mixed sample of dyadic pairs,
adult subjects and caregivers of pediatric subjects. Analyses were conducted by
group and total sample. RESULTS: Confirmatory factor analysis provided evidence
for a second order factor solution for four subscales and a total IPAQ score; and
supported the conceptual framework developed from previous qualitative and
quantitative research. Although IPAQ subscales did not consistently meet accept-
able internal consistency reliability for some group level comparisons, the total
IPAQ score showed high internal consistency for both pens (Cronbach’s alpha 
0.77 – 0.86). In general, the construct validation (predictive validity) findings were
consistent across pens and across subject groups and generally consistent with
those from the US trial. CONCLUSIONS: The IPAQ total score for ease of use dem-
onstrated good internal consistency reliability and good construct validity in mea-
suring ease of use with injection pens to administer rhGH. Findings from this
research are consistent with those from the US-based study, supporting the use-
fulness of the IPAQ total score in evaluating ease of use and preference for injection
pens in clinical trials and in practice.
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OBJECTIVES: There are no existing patient reported outcome (PRO) measures in
Type 2 Diabetes Mellitus (T2DM) developed in accordance with FDA Guidance on
PROs. The objective of this study was to develop and validate a T2DM-specific PRO
measure examining hypoglycemic symptoms (HS), weight neutrality (WN), medi-
cation tolerability (MT), and medication compliance (MC). METHODS: The Diabe-
tes-Management and Impact Questionnaire (D-MIQ) and the Diabetes-Assessment
of Blood Sugar Questionnaire (D-ABS) were developed in three phases: concept
elicitation (CE; n20), item generation, and cognitive interviews (CIs; n20). The
D-ABS was finalized as a 36-item PRO assessing HS with a yes/no response scale
measuring symptom frequency and an 11-point numeric response scale measuring
symptom severity. The D-MIQ was finalized as an 18-item PRO measuring impacts
of HS, WN, MT, and MC, with four- and five-point Likert-type response scales and a
yes/no scale. Following content validation, a stand-alone observational study was
conducted in 100 subjects to assess the psychometric properties of the D-MIQ and
D-ABS. RESULTS: Subjects had a mean age of 57.4 (SD 12.6) years (52% female, 60%
white). All items on the D-ABS and D-MIQ showed good convergent validity with
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the instruments’ Total Symptom Scores (TSS; item-scale correlations0.40). Inter-
nal consistency was strong (D-ABS TSS 0.92; D-MIQ Worries of Hypoglycemia
0.70; WN 0.90). Test-retest reliability was acceptable for both instruments
(D-ABS TSS ICC0.66; D-MIQ Worries of Hypoglycemia ICC0.65 WN ICC0.92).
CONCLUSIONS: The D-ABS and D-MIQ are psychometrically valid surveys for the
assessment of symptoms and impacts for T2DM. The surveys developed in this
study reduce the time required for the assessment of HS frequency and severity
(D-ABS), MC and MT, and weight impact (D-MIQ) in T2DM patients. The combina-
tion of psychometric validity and assessment time reduction make the D-ABS and
D-MIQ a viable means for in-trial and clinical assessment of HS and impacts.
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OBJECTIVES: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a novel class
of drugs to treat patients with Type 2 Diabetes Mellitus (T2DM). The attributes of
the SGLT2i differ from those of other medications. Therefore, patients’ preferences
for each of these attributes are of potential interest to patients, physicians, and
payers.METHODS:A discrete choice experiment was conducted with patients with
T2DM from the UK to examine 7 attributes of T2DM medications: efficacy (defined
as reduction in blood glucose levels), urinary tract infection/genital infection side-
effects, weight change, gastrointestinal/nausea side-effects, hypoglycemic events,
blood pressure, and cardiovascular risk. Patients were presented with 20 total
choices between 2 hypothetical T2DM medications each described by varying lev-
els of the 7 attributes. Partial utilities were estimated using random effects multi-
logit models, and relative importance (RI) values were calculated for each of the
attributes. Data were analyzed for the overall sample, and by medication and gen-
der subgroups. RESULTS: One hundred patients with T2DM completed the study
(51% male; mean age62.9, SD11.1 years; mean BMI32.7, SD6.5; 50.0% taking
2T2DM medications). The four most important attributes to patients were: risk of
hypoglycaemic events (relative importance (RI) 24.7%), weight change associated
with the medication (RI20.6%), risk of gastrointestinal/nausea side-effects
(RI18.6%), and efficacy (RI18.0%). The remaining attributes were of lesser impor-
tance: risk of urinary tract infection/genital infection side-effects (RI9.9%), car-
diovascular risk (RI4.3%), and blood pressure changes (RI3.9%). Additional re-
sults for subgroup analyses will be presented. CONCLUSIONS: Patients with T2DM
consider the risk of hypoglycaemic events, weight changes associated with a med-
ication, the risk of gastrointestinal/nausea side-effects, and the efficacy of a med-
ication to be attributes of approximately equivalent importance for T2DM medica-
tions. Prescribing physicians should consider these characteristics of medications
as they may contribute to patients’ overall satisfaction with their diabetes therapy.
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OBJECTIVES: Generic preference-based measures such as EQ-5D and SF-6D and
condition specific measures such as the Diabetes Health Profile-18 (DHP-18) are
used in the assessment of health related quality of life in diabetes. The aim of this
study was to investigate the psychometric acceptability, validity and responsive-
ness of these measures in a type 2 diabetes population. METHODS: Acceptability
was assessed by calculating missing data rates. We investigated the convergent
validity of the measures using correlations, known group validity across a variety
of clinical indicators using ANOVA, and agreement between the measures using
Intra Class Correlation coefficients (ICC) and Bland Altman plots. Responsiveness
to change over time was assessed using standardised response mean, and floor/
ceiling effect tests. A UK longitudinal sample of 1613 people with Type 2 diabetes
was used for the analysis.RESULTS:Overall rates of missing data were less than 5%
indicating acceptability to respondents. Across both time points, the DHP-18 di-
mensions were moderately correlated with the EQ-5D and SF-6D indicating con-
struct validity. All three measures significantly discriminated between those re-
porting and not reporting co-morbid health problems. In terms of agreement, the
ICC between the preference based measures was high, and Bland Altman plots
indicated that agreement is higher at the less severe end of the scale. The EQ-5D
displays evidence of a ceiling effect, and for patients self reporting change in
health, SRM statistics indicate that the sensitivity to change across time is low for
all measures.CONCLUSIONS:There is evidence for the psychometric validity of the
generic preference based measures EQ-5D and SF-6D and the condition specific
DHP-18 to measure outcomes in diabetes. However evidence for the responsive-
ness of the measures is less clear. The inclusion of both generic and condition
specific measures in trials may increase the accuracy of outcomes assessment in
type 2 diabetes.
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OBJECTIVES: Intensive glycemic control can increase the risk of hypoglycemia
among type 2 diabetes (T2D) patients, especially for people treated with insulin or
sulfonylureas. The goal of this study was to establish the content validity of a new
patient-reported outcome (PRO) instrument assessing multiple dimensions of the
patient’s experience of hypoglycemia – the Hypoglycemia Perspectives Question-
naire (HPQ). METHODS: The study included concept evaluation (to identify key
hypoglycemia perspectives to be assessed in the instrument), item generation, and
cognitive interviewing (to assess patient understanding of the HPQ) phases. The
concept evaluation phase included interviews with 19 T2D patients (mean age 
54.4, 37% male, 74% Caucasian) and 4 key opinion leaders, and a targeted review of
the literature. Two phases of cognitive interviews were conducted with T2D pa-
tients (Phase I: n6; Phase II: n5; 55% male, 45%  50 years old, 82% Caucasian);
changes to the HPQ were made in between phases. In concept elicitation and
cognitive interviews, respondents were interviewed one-on-one by a trained mod-
erator using a semi-structured interview guide. RESULTS: Key concepts emerging
from the concept evaluation phase included: frequency and severity of events,
emotional response to a hypoglycemia event, symptom concern, importance of
compensatory behaviors, personal control, worries, functional impact, and aware-
ness of symptoms. Tremor (79% of patients), dizziness (68%), and sweating (63%)
were the most commonly reported symptoms. Items were generated to assess the
key dimensions of hypoglycemia. The HPQ instructions, items, and response op-
tions were generally understood and only minor changes were made to the
instrument. CONCLUSIONS: The HPQ is a PRO instrument that can be used in
studies of T2D patients. It provides a comprehensive assessment of the patient’s
perspectives on hypoglycemia that goes beyond existing instruments. Once the
items are finalized via psychometric testing, the HPQ may be used to evaluate the
burden of hypoglycemia.
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OBJECTIVES: Fear for hypoglycemia has an impact on type 2 diabetes mellitus
(T2DM) patients’ Health-Related Quality of Life (HRQoL). The Worry Subscale of the
Hypoglycaemic Fear Survey-II (HFS-II) is a widely used tool. The objective is to test
the internal consistency, validity and reliability of a Spanish version of HFS-II for
determining the impact of fear for hypoglycemia on T2DM patients’ HRQL in Spain.
METHODS: Observational, cross-sectional, multicentre design. T2DM patients di-
agnosed from at least 1 year were recruited consecutively. Use of research tools:
1)Audit of Diabetes-Dependent Quality of Life/ADDQoL questionnaire [-9 to 9,
more negative scores indicate greater negative impact of diabetes on QoL];2)Worry
subscale of HFS-II [0-72, higher scores indicate increased fear];3)Visual Analogue
Scales (VAS) [0-10, higher scores indicate greater fear and impact of hypoglycemia].
For determining HSF-II internal consistency, validity and reliability, next parame-
ters were calculated: Cronbach’s alpha; ceiling/floor effects; correlations between
similar items scores of HFS-II/ADDQoL and between scores of two anchor ques-
tions (VAS) /HFS-II. RESULTS: A total of 3,812 patients (661 health care centers)
participated in the study [men (53.57%);mean(SD) age 63.70(11.37) years;mean(SD)
time from T2DM diagnosis 9.67(6.91) years]. 44.88% of patients referred at least one
episode of hypoglycemia in the previous six months. Mean(SD) HFS-II subscale
score was 24.41(17.05). It was higher in patients with hypoglycemia [31.32(15.71)]
compared to those without [18.85(16.03)](p0.0001). Cronbach’s alpha was 0.964. A
negative correlation was found between ADDQoL and HFS-II mean scores (-0.441;
p0.0001). Items that explore physical capacity, family, confidence, motivation,
future and dependence in ADDQoL and in HFS-II showed the highest correlations.
Anchorage questions’ (VAS) correlations (0.522-0.597) demonstrated an acceptable
face validity of the HFS-II individual items. Ceiling/floor effects below 20% suggest
its good functionality. CONCLUSIONS: These preliminary results show that the
HFS-II is consistent, valid and reliable for assessing fear for hypoglycemia in T2DM
patients in Spain.
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PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
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OBJECTIVES: To know the incidence and cost of hypoglycemia episode in patients
with type 2 diabetes mellitus (T2DM) in China METHODS: A face-to face interview
was performed in 2 hospitals in Beijing and Tianjin with a well designed question-
naire. The incidence of mild, moderate and severe hypoglycemia as well as the
daily prevention cost and management cost per event were collected and investi-
gated in this study. RESULTS: The overall incidence of the study population was
54.04% within 1 year. A total 146 mild hypoglycemia episodes were reported in 79
patients within 1 week. A total 54 moderate hypoglycemia episodes were reported
in 37 patients within 1 month. A total 6 severe hypoglycemia episodes were re-
ported in 6 patients within 1 year. The well controlled (Fast Blood Glucose )FBG
group experienced the most mild hypoglycemia episodes and the group with treat-
ment of oral hypoglycemic agents combined with insulin had the highest hypogly-
cemia incidence within 1 year. The mean costs for mild, moderate and severe
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